期刊文献+

新型糖原磷酸化酶抑制剂-山楂酸对小鼠脑缺血-再灌注的保护作用研究 被引量:5

Effects of maslinic acid as a novel glycogen phosphorylase inhibitor on cerebral ischemia in mice
下载PDF
导出
摘要 目的:研究糖原磷酸化酶抑制剂-山楂酸对缺血性脑损伤的保护作用,初步探讨糖原磷酸化酶抑制剂的脑缺血保护机制。方法:采用合并迷走神经结扎双侧颈总动脉造成小鼠急性不完全性脑缺血-再灌注模型,测定脑组织匀浆乳酸含量、相关生化指标以及肝糖原含量。结果:山楂酸灌胃给药以后能降低脑组织乳酸、丙二醛含量,提高超氧化物歧化酶、乳酸脱氢酶活力,还能对抗缺血期间的肝糖原降解。结论:山楂酸对缺血性脑损伤具有一定保护作用,其抗脑缺血作用至少是与通过部分抑制糖酵解并进而减轻代谢性酸中毒有关。 AIM: This experiment was designed to study the protective effects of maslinic acid, a novel glycogen phosphorylase inhibitor, on cerebral ischemia in mice. METHODS: The model of acute cerebral ischemia-reperfusion in mice was set up by ligating bilateral common carotid artery and vagus, thus blocking the blood stream for 90 s, and subjecting mice to 5 rain reperfusion. Brain samples were prepared to observe the cerebral injury; liver samples were prepared to observe the status of hepatic glucose metabolism, which contribute to the observed hyperglycemia during cerebral ischemia. RESULTS: Maslinic acid significantly reduced the lactate and MDA level, increased SOD and LDH activity and preserved the hepatic glycogen after mice were subjected to acute cerebral ischemia-reperfusion. CONCLUSION: Maslinic acid may exert its potential protective effects against cerebral ischemic injury, at least in part, through inhibition of over degradation of cerebral glycogen and thus reducing lactate production during ischemia.
出处 《中国临床药理学与治疗学》 CAS CSCD 2007年第4期381-384,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 教育部"2005年度新世纪优秀人才支持计划"资助项目(NCET-05-0495) 高等学校博士学科点专项科研基金资助项目(Y051018)
关键词 脑缺血 再灌注损伤 乳酸中毒 糖原磷酸化酶抑制剂 山楂酸 cerebral ischemia ischemia-reperfusion injury lactate acidosis glycogen phosphorylase inhibitors maslinic acid
  • 相关文献

参考文献1

二级参考文献41

  • 1Chandy MJ,Ravindra J. Effect of dichloracetate on infarct size in a primate model of focal cerebral ischaemia [J]. Neurol India, 2000,48; 227 - 230. 被引量:1
  • 2Niwa M, Hara A, Iwai T, et al. Prevention of ischemia-induced hippocampal neuronal damage by 2-deoxy-D-glucose in gerbils[J].Life Sci, 1999,64(18) : PL193 - PL198. 被引量:1
  • 3Oudard S, Poirson F, Miccoli L, et al. Mitochondria-bound hexokinase as target for therapy of malignant gliomas[J]. Intern J Cancer, 1995,62(2) :216 - 222. 被引量:1
  • 4Tidmarsh G. Treatment of benign prostatic hyperplasia: PCT,W02004064735 [P]. 2005-08-05. 被引量:1
  • 5Claustre S, Denier C, Lakhdar-Ghazal F, et al. Exploring the active site of trypanosoma brucei phosphofructokinase by inhibition studies:specific irreversible inhibition[J], Biochem,2002,41(32):10183 -10193. 被引量:1
  • 6Guminska M, Kedryna T, Marchut E. The effect of levamisole on energy-metabolism in ehrlich ascites tumor-cells in vitro [J].Biochem Pharmacol, 1986,35(24) :4369-4374. 被引量:1
  • 7Tidmarsh G. Treatment of cancer with 2-deoxyglucose: US,US2005245462 [P]. 2005-11-03. 被引量:1
  • 8Lampidis T, Priebe W. Manipulation of oxidative phosphorylation for hypersensitizing tumor cells to glycolytic inhibitors: PCT, W00182926[P].2001-11-08. 被引量:1
  • 9Veyhl M. Wagner K, Volk C, et al. Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard(D-19575) into tumor cells is mediated by the Na^+ -D-glucose cotransporter SAAT1[J]. Proc Natl Aatcl Sci USA, 1998,95 (6) :2914-2919. 被引量:1
  • 10Briasoulis E, Pavlidis N, Terret C, et al. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase Ⅱ trial of the EORTC-new drug development group[J]. Eur J Carwer ,2003,39(16) :2334-2340. 被引量:1

共引文献10

同被引文献157

引证文献5

二级引证文献137

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部